These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 35759082)

  • 1. Immunotherapy: an alternative promising therapeutic approach against cancers.
    Gupta SL; Basu S; Soni V; Jaiswal RK
    Mol Biol Rep; 2022 Oct; 49(10):9903-9913. PubMed ID: 35759082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy beyond immune checkpoint inhibitors.
    Marin-Acevedo JA; Soyano AE; Dholaria B; Knutson KL; Lou Y
    J Hematol Oncol; 2018 Jan; 11(1):8. PubMed ID: 29329556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of cancer immunotherapeutic strategies.
    Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
    Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.
    Kumar AR; Devan AR; Nair B; Vinod BS; Nath LR
    Mol Biol Rep; 2021 Dec; 48(12):8075-8095. PubMed ID: 34671902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach.
    Entezam M; Sanaei MJ; Mirzaei Y; Mer AH; Abdollahpour-Alitappeh M; Azadegan-Dehkordi F; Bagheri N
    Life Sci; 2023 Apr; 318():121459. PubMed ID: 36720453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy: the beginning of the end of cancer?
    Farkona S; Diamandis EP; Blasutig IM
    BMC Med; 2016 May; 14():73. PubMed ID: 27151159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies in cancer immunotherapy.
    Kimiz-Gebologlu I; Gulce-Iz S; Biray-Avci C
    Mol Biol Rep; 2018 Dec; 45(6):2935-2940. PubMed ID: 30311129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for pancreatic cancer: A long and hopeful journey.
    Xu JW; Wang L; Cheng YG; Zhang GY; Hu SY; Zhou B; Zhan HX
    Cancer Lett; 2018 Jul; 425():143-151. PubMed ID: 29605510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in ovarian cancer.
    Krishnan V; Berek JS; Dorigo O
    Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors.
    Du Y; Liu Y; Wang D; Bai H; Wang Z; He X; Zhang P; Tian J; Wang J
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel approaches in cancer immunotherapy.
    Subramaniam DS; Liu SV; Giaccone G
    Discov Med; 2016 Apr; 21(116):267-74. PubMed ID: 27232512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy a New Hope for Cancer Treatment: A Review.
    Nouri Rouzbahani F; Shirkhoda M; Memari F; Dana H; Mahmoodi Chalbatani G; Mahmoodzadeh H; Samarghandi N; Gharagozlou E; Mohammadi Hadloo MH; Maleki AR; Sadeghian E; Nia E; Nia N; Hadjilooei F; Rezaeian O; Meghdadi S; Miri S; Jafari F; Rayzan E; Marmari V
    Pak J Biol Sci; 2018; 21(3):135-150. PubMed ID: 30187723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future immunotherapeutic approaches in pancreatic cancer treatment.
    Farhangnia P; Khorramdelazad H; Nickho H; Delbandi AA
    J Hematol Oncol; 2024 Jun; 17(1):40. PubMed ID: 38835055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The State of Immunotherapy in Hepatobiliary Cancers.
    Ilyas FZ; Beane JD; Pawlik TM
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.
    Lohmueller J; Finn OJ
    Pharmacol Ther; 2017 Oct; 178():31-47. PubMed ID: 28322974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.